Encephalopathy News and Research

RSS

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Oxeia accelerating development of neurometabolic treatments for concussions

Oxeia Biopharmaceuticals, Inc., a biotechnology company, is catalyzing the development of first-in-class neurometabolic treatments for concussions and other aspects of brain injury.

21 Jan 2016

Study findings may help explain why risk of stroke changes after menopause

Risk of stroke in women may come down to a compound the body produces from estrogen known as 2-methoxyestradiol (2-ME). Furthermore, the compound's therapeutic potential may extend beyond treating stroke in women to healing brain injuries in men, a new study in American Journal of Physiology—Endocrinology and Metabolism reports.

20 Jan 2016

Concussions related to sports and recreation activities affect millions of Americans

Every year, between 3 million and 4 million Americans suffer concussions in sports and recreation. Head impacts and concussions caused by contact sports are a quickly growing epidemic among young athletes.

19 Jan 2016

New UTMB study reveals link between traumatic brain injury and Alzheimer's disease

A new study from The University of Texas Medical Branch at Galveston fills an important gap in understanding the link between traumatic brain injury and neurodegenerative disorders such as Alzheimer's disease.

13 Jan 2016

Researchers awarded $16 million NIH/NINDS grant to create methods for detecting CTE during life

Researchers from Boston University, the Cleveland Clinic, Banner Alzheimer's Institute and Brigham and Women's Hospital in Boston, have been awarded a $16 million grant from the National Institutes of Health/National Institute of Neurological Disorders and Stroke.

23 Dec 2015

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

European liver patients’ association launches call to action report for the treatment of heapatic encephalopathy

ELPA today launched a new call to action report ‘Time to DeLiver: Getting a Grip on HE’ at the European Parliament in Brussels. This is the first report from Europe to highlight the significant burden of hepatic encephalopathy on patients, their carers, families and society.

14 Oct 2015

Study confirms neuroprotective effects of hypothermia in newborns with HIE

A unique study at Children's Hospital Los Angeles of newborns treated with hypothermia for hypoxic-ischemic encephalopathy (HIE) - a condition that occurs when the brain is deprived of an adequate oxygen supply - confirms its neuroprotective effects on the brain.

9 Oct 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

New concussion program aims at treating football players with predisposition to CTE

Upledger Institute Clinic in conjunction with the Ricky Williams Foundation and the Dr. John E. Upledger Foundation announced earlier today, the start of their second concussion therapy research program aimed at treating current and former members of the NFL and the Canadian Football League.

26 Sep 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Regular physical trauma may put professional football players at increased risk for hypertension

The regular physical trauma that appears to put professional football players at risk for degenerative brain disease may also increase their risk for hypertension and cardiovascular disease, researchers say.

9 Sep 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

Newly discovered prion causes Multiple System Atrophy

Multiple System Atrophy (MSA), a neurodegenerative disorder with similarities to Parkinson's disease, is caused by a newly discovered type of prion, akin to the misfolded proteins involved in incurable progressive brain diseases such Creutzfeldt-Jakob Disease (CJD), according to two new research papers led by scientists at UC San Francisco.

1 Sep 2015

FAU neuroscientist develops Quick Dementia Rating System comparable to gold standard clinical tests

Determining whether or not an individual has dementia and to what degree is a long and laborious process that can take an experienced professional such as a clinician about four to five hours to administer, interpret and score the test results. A leading neuroscientist at Florida Atlantic University has developed a way for a layperson to do this in three to five minutes with results that are comparable to the "gold standard" dementia tests used by clinicians today.

13 Aug 2015

Early exposure to repetitive head impacts linked to later life structural brain changes among former NFL players

Former National Football League (NFL) players who started playing tackle football before the age of 12 were found to have a higher risk of altered brain development compared to those who started playing at a later age. The study is the first to demonstrate a link between early exposure to repetitive head impacts and later life structural brain changes.

11 Aug 2015

New study reveals how infectious proteins spread from gut to the brain

Diagnosis of deadly brain conditions could be helped by new research that shows how infectious proteins that cause the disease spread.

5 Aug 2015

Extremes of stroke symptoms attract misdiagnoses

Patients with very mild or very severe stroke symptoms are at the greatest risk of being misdiagnosed in the emergency department, research suggests.

24 Jul 2015